Detection of resistance to imatinib by metabolic profiling: Clinical and drug development implications

American Journal of PharmacoGenomics

Volumn 5, Issue 5, 2005, Pages 293-302

  Serkova, Natalie ^a   Boros, László G ^b,c  

^a UNIVERSITY OF COLORADO   (United States)

^b SIDMAP LLC   (United States)

^c LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; FATTY ACID; FK 866; GLUCOSE; IMATINIB; STABLE ISOTOPE; UNCLASSIFIED DRUG;

BONE MARROW CELL; BREAST TUMOR; CARBON NUCLEAR MAGNETIC RESONANCE; CELL ISOLATION; CELL METABOLISM; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; DISEASE COURSE; DRUG RESISTANCE; DRUG TARGETING; ENERGY; FATTY ACID SYNTHESIS; GAS CHROMATOGRAPHY; GASTROINTESTINAL TUMOR; GENE EXPRESSION; GENETICS; GLIOBLASTOMA; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; ISOTOPE LABELING; LACTATION; LEUKEMIA; MASS SPECTROMETRY; METABOLISM; MONITORING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATION; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN EXPRESSION; REVIEW; RNA SYNTHESIS; SENSITIVITY ANALYSIS; SYNTHESIS; TECHNOLOGY; TUMOR CLASSIFICATION; TUMOR DIAGNOSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 26444469502     PISSN: 11752203     EISSN: 11752203     Source Type: Journal    
DOI: 10.2165/00129785-200505050-00002     Document Type: Review

References (55)

1. Gadian DG. NMR applications to living systems. 2nd ed. London: Oxford University Press, 1995
2. Savage DG, Antman KH. Imatinib mesylate: a new oral targeted therapy. N Engl J Med 2002; 346: 683-93
3. Deiniger MWN, Goldman JM, Lydon N, et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL positive cells. Blood 1997; 90: 3691-8
4. Vigneri P, Wang JY. Indication of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med 2001; 7: 228-34
5. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the ABL proteintyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996; 56: 100-4
6. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002; 347: 481-7
7. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002 Aug 15; 347 (7): 472-80
8. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-7
9. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia [published erratum appears in N Engl J Med 2002, 347: 68]. N Engl J Med 2002; 346: 645-52
10. Von Bubnoff N, Schneller F, Peschel C, et al. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukemia to STI571: a prospective study. Lancet 2002; 359: 487-91
11. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-80
12. Goldman JM, Melo JV. Chronic myeloid leukemia: advances in biology and new approaches to treatment. N Engl J Med 2003 Oct 9; 349 (15): 1451-64
13. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002; 100: 1014-8
14. Campbell LJ, Patsouris C, Rayeroux KC, et al. BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration. Cancer Genet Cytogenet 2002; 139: 30-3
15. Mahon FX, Belloc F, Lagarde V, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003; 101: 2368-73
16. Ferrao PT, Frost MJ, Siah SP, et al. Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro. Blood 2003 Dec 15; 102 (13): 4499-4503. Epub 2003 Jul 24
17. Tipping AJ, Mahon FX, Lagarde V, et al. Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells. Blood 2001; 98: 3864-7
18. Gatto S, Scappini B, Pham L, et al. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in BCR/ABL-positive cell lines sensitive and resistant to imatinib mesylate. Haematologica 2003; 88: 853-63
19. Mountford CE, Doran S, Lean CL, et al. Cancer pathology in the year 2000. Biophys Chem 1997; 68: 127-35
20. Gillies RJ, Bhujwalla ZM, Evelhoch J, et al. Applications of magnetic resonance in model systems: tumor biology and physiology. Neoplasia 2000; 2: 139-51
21. Evelhoch JL, Gillies TJ, Karczmar GS, et al. Applications of magnetic resonance in model systems: cancer therapeutics. Neoplasia 2000; 2: 152-65
22. Griffin JL, Shockcor JP. Metabolic profiles of cancer cells. Nat Rev Cancer 2004; 4: 551-61
23. Cornel EB, Heerschap A, Smits GA, et al. Magnetic resonance spectroscopy detects metabolic differences between seven Dunning rat prostate tumor sublines with different biological behavior. Prostate 1994; 25: 19-28
24. Menard C, Smith IC, Somorjai RL, et al. Magnetic resonance spectroscopy of the malignant prostate gland after radiotherapy: a histopathologic study of diagnostic validity. Int J Radiat Oncol Biol Phys 2001; 50: 317-23
25. McKnight TR. Proton magnetic resonance spectroscopic evaluation of brain tumor metabolism. Semin Oncol 2004; 31: 605-17
26. Pucar D, Koutcher JA, Shah A, et al. Preliminary assessment of magnetic resonance spectroscopic imaging in predicting treatment outcome in patients with prostate cancer at high risk for relapse. Clin Prostate Cancer 2004 Dec; 3 (3): 174-81
27. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipids metabolism of human mammary epithelial cells. Cancer Res 1999; 59: 80-4
28. Glunde K, Ackerstaff E, Natarajan K, et al. Real-time changes in 1H and 31P NMR spectra of malignant human mammary epithelial cells during treatment with the anti-inflammatory agent indomethacin. Magn Reson Med 2002; 48: 819-25
29. Franks SE, Smith MR, Arias-Mendoza F, et al. Phosphomonoester concentrations differ between chronic lymphocytic leukemia cells and normal human lymphocytes. Leukemia Res 2002; 26: 919-26
30. Anthony ML, Zhao M, Brindle KM. Inhibition of phosphatidylcholine biosynthesis following induction of apoptosis in HL-60 cells. J Biol Chem 1999; 274: 19686-92
31. Ronen SM, DiStefano F, McCoy CL, et al. Magnetic resonance detects metabolic changes associated with chemotherapy-associated apoptosis. Br J Cancer 1999; 80: 1035-41
32. Williams SN, Anthony ML, Brindle KM. Induction of apoptosis in two mammalian cell lines results in increased levels of fructose-1,6-biphosphate and CDP-choline as determined by 31P-MRS. Magn Reson Med 1998; 40: 411-20
33. Muruganandham M, Alfieri AA, Matei C, et al. Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy. Clin Cancer Res 2005; 11: 3503-13
34. Kuliszkiewicz-Janus M, Baczynski S, Jurczyk A. Bone marrow transplantation in the course of hematological malignancies: follow-up study in blood serum by 31P MRS. Med Sci Monit 2004; 10: 485-92
35. Ronen SM, Leach MO. Imaging biochemistry: applications to breast cancer. Breast Cancer Res 2001; 3: 36-40
36. Boros LG, Williams RD. Isofenphos induced metabolic changes in K562 myeloid blast cells. Leuk Res 2001; 25: 883-90
37. Zhou R, Vander Heiden MG, Rudin CM. Genotoxic exposure is associated with alterations in glucose uptake and metabolism. Cancer Res 2002; 62: 3515-20
38. Bernes-Price SJ, Sant ME, Christopherson RI, et al. 1H and 31P NMR and HPLC studies on mouse L1210 leukemia cell extracts: the effect of AU(I) and Cu(I) diphosphine complexes on the cell metabolism. Magn Reson Med 1991; 18: 142-58
39. Boros LG, Cascante M, Lee WN. Metabolic profiling of cell growth and death in cancer: applications in drug discovery. Drug Discov Today 2002; 7: 364-72
40. Boros LG, Lee WN, Go VL. A metabolic hypothesis of cell growth and death in pancreatic cancer. Pancreas 2002; 24: 26-33
41. Boros LG, Lerner MR, Morgan DL, et al. [1,2-13C2]-D-glucose profiles of the serum, liver, pancreas and DMBA-induced pancreatic tumors of rats. Pancreas 2005, In press
42. Boros LG, Lee WNP, Cascante M. Imatinib and chronic-phase leukemias. N Engl J Med 2002; 347: 67-8
43. Boros LG, Brackett DJ, Harrigan GG. Metabolic biomarker and kinase target discovery in cancer using stable isotope-based dynamic metabolic profiling (SIDMAP). Curr Cancer Drug Target 2003; 3: 447-55
44. Gottschalk S, Anderson N, Miljus J, et al. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL positive cells. Clin Cancer Res 2004; 10: 6661-8
45. Miljus J, Melo JV, Boros LG, et al. Metabolic profile of imatinib resistance in chronic myeloid leukemia cells. 46th American Society of Hematology Annual Meeting and Exposition; 2004 Dec 4-7; San Diego (CA)
46. Sahai I, Montefusco MC, Fleming JC, et al. Role of defective high-affinity thiamine transporter slc19a2 in marrow from a mouse model of thiamine-responsive anemia syndrome: evidence for defective deoxyribose and heme synthesis. 47th American Society of Hematology Annual Meeting; 2005 Dec 4-6; Atlanta (GA).
47. O'Reilly T, Wartmann M, Maira SM, et al. Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma. Cancer Chemother Pharmacol 2004; 55: 307-17
48. Dresemann G. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann Oncol 2005 Jul 20. Epub ahead of print
49. Kilic T, Alberta JA, Zdunek PR, et al. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res 2000 Sep 15; 60 (18): 5143-50
50. Hagedorn M, Javerzat S, Gilges D, et al. Accessing key steps of human tumor progression in vivo by using an avian embryo model. Proc Natl Acad Sci USA 2005 Feb 1; 102(5): 1643-8
51. Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005; 44 (9): 879-94
52. Chevanne M, Caldini R. Relationship between pyridine nucleotide levels and ribonucleotide reductase activity in Yoshida ascites hepatoma AH130. Exp Cell Res 1986 Dec; 167 (2): 327-36
53. Van den Abbeele AD, Balawi RD. Use of positron emission tomography (PET) in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 2002; 38: S60-5
54. Buchanan TA, Xiang A, Kjos SL, et al. Gestational diabetes: antepartum characteristics that predict postpartum glucose intolerance and type 2 diabetes in Latino women. Diabetes 1998; 47: 1302-10
55. Garg M, Bassilian S, Bell C, et al. Hepatic de novo lipogenesis in stable low-birth-weight infants during exclusive breast milk feedings and during parenteral nutrition. JPEN J Parenter Enteral Nutr 2005; 29: 81-6